Abstract Library

#3062 The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features

Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Alors-Pérez E

Authors: Alors-Pérez E, Pedraza-Arévalo S, Vázquez-Borrego M, Blázquez-Encinas R, Herrera-Martínez A,

Keywords: PanNET, CELF4, splicing, aggressiveness, pituitary tumors,

#3053 The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors

Introduction: Alternative splicing dysregulation is increasingly regarded as a novel cancer hallmark influencing all key tumor features. We have shown that neuroendocrine tumors (NETs) overexpress aberrantly spliced variants of neuropeptides and receptors that increase tumor malignancy. More recently, we discovered that the splicing machinery is dysregulated in pituitary and pancreatic NETs. To date, the status of this machinery in low grade pulmonary NETs is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Blázquez-Encinas R

Authors: Blázquez-Encinas R, Caro M, Pedraza-Arévalo S, Alors-Pérez E, Herrera-Martínez A,

Keywords: low grade pulmonary NETs, splicing, splicing machinery, malignancy,

#2141 Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells

Introduction: Extracellular fragments derived from membrane receptors can play relevant functional roles in certain tumoral pathologies and could provide novel diagnostic or therapeutic tools. We have identified a novel truncated somatostatin receptor type 5 variant, sst5TMD4, which is overexpressed and functionally active in different endocrine-related cancers, including neuroendocrine tumors (NETs). Interestingly, sst5TMD4 has 4 transmembrane domains and its C-terminal tail is consequently exposed towards the extracellular matrix, and could, therefore, be the substrate for proteolytic enzymes.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pedraza-Arévalo S, Del Río-Moreno M, Alors-Pérez E, Castaño J, Luque R,

Keywords: sst5TMD4, derived peptides, malignancy, endocrine-related cancer,

#1875 Potential Anti-Tumor Activity of Biguanides and Statins in Neuroendocrine Tumor Cells

Introduction: Recent studies have suggested that biguanides and statins have beneficial effects on various cancer types; however, the precise effects and the molecular mechanisms underlying this pathophysiological association are still not well understood in neuroendocrine tumor (NETs).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Herrera-Martínez A, Pedraza-Arévalo S, López-López F, Gahete M, Gálvez-Moreno M,

Keywords: NETs,biguanides,statins,

#1566 Splicing Dysregulation Impacts on Neuroendocrine Tumors: Evidence from Altered Spliceosoma Components and Somatostatin and Ghrelin Systems.

Introduction: Splicing is an emerging cancer hallmark influencing multiple tumor cell (dys)functions. We have shown that aberrantly spliced variants of somatostatin receptor subtype 5 (sst5TMD4) and of the pleiotropic neuropeptide ghrelin (in1ghrelin) are linked to poor prognosis in gastroenteropancreatic neuroendocrine tumors (GEPNETs) and may enhance their aggressiveness features.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Castaño J

Authors: Castaño J, Pedraza-Arevalo S, Herrea-Martinez A, Del Río-Moreno M, Sánchez-Sánchez R,

Keywords: Splicing,